IONSIonis Pharmaceuticals
About Ionis Pharmaceuticals
Ionis Pharmaceuticals (NASDAQ:IONS) specializes in RNA-targeted drug discovery and development, focusing on creating innovative medicines to treat severe and rare diseases. Their robust pipeline includes projects aimed at combating a variety of conditions, including cardiovascular, metabolic, neurological, and pulmonary diseases, as well as cancer. The company leverages its proprietary technology platform to develop drugs that precisely target specific genetic material, silencing the genes that cause disease. Ionis's objective is to continue expanding its pipeline through both in-house research and strategic partnerships, aiming to address unmet medical needs and improve patients' lives around the world.
What is IONS known for?
Snapshot
Public US
Ownership
1989
Year founded
987
Employees
Carlsbad, United States
Head office
1 of 3
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Carlsbad, US
Products and/or services of Ionis Pharmaceuticals
- SPINRAZA, a treatment for spinal muscular atrophy, transforming the lives of those affected by this genetic disorder.
- TEGSEDI, offers hope for patients with hereditary TTR amyloidosis, addressing polyneuropathy symptoms.
- WAYLIVRA, designed to combat familial chylomicronemia syndrome, offers a novel approach to managing this rare genetic lipid disorder.
- Fomivirsen, an antiviral used in the treatment of cytomegalovirus retinitis, showcases the company's innovative approach to RNA-targeted therapies.
- HUNTINGTON'S DISEASE PROGRAM, developing treatments to address the unmet needs of Huntington's disease, aiming to halt or reverse the disease progression.
- ALS PROGRAM, focuses on creating therapeutic solutions for amyotrophic lateral sclerosis, striving to significantly improve patient outcomes.
Ionis Pharmaceuticals executive team
- Dr. Brett P. Monia Ph.D.Founder, CEO & Director
- Ms. Elizabeth L. Hougen M.A., M.B.A., M.S.Executive VP of Finance & CFO
- Mr. Patrick R. O'Neil Esq.Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary
- Mr. Kyle JenneExecutive VP & Chief Global Product Strategy Officer
- Mr. Darren GonzalesChief Accounting Officer & Senior VP
- Dr. C. Frank Bennett BSc, Ph.D.Executive VP & Chief Scientific Officer
- Mr. D. Wade Walke Ph.D.Senior Vice President of Investor Relations
- Ms. Tracy Berns J.D.Senior VP and Chief Compliance & Quality Assurance Officer
- Ms. Hayley SofferVice President of Corporate Communications
- Ms. Shannon L. Devers DeversExecutive VP & Chief Human Resource Officer